The article you requested is
Antiepileptic Drug Augmentation for Treatment-Resistant Depression
J Clin Psychiatry 1997;58:361-362 [letter]
Copyright 1997 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
Purchase this PDF for $40
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP print + online for $166 individual.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send an email
Letter to the Editor
Sir: The recent case report by Ketter, Callahan, and Post1 illustrating
a positive therapeutic drug/drug interaction for
treatment-resistant anxious depression is an example of outstanding
psychopharmacologic strategizing. The authors explain
their successful outcome, achieved when nefazodone was
added to alprazolam, with a pharmacokinetic model, hypothesizing
that nefazodone extended the duration of action of alprazolam
through inhibiting its degradation by the cytochrome
P450 3A3/4 system, thereby eliminating “interdose dysphoria.”